For global developers of rare disease drugs, China and its 1.4 billion population may offer relatively large pools of patients with such disorders. Clinical data derived from trials in the country can also be used to help speed up clinical studies in the US or Europe.
NGGT Progresses First US Gene Therapy Trials For Rare Conditions
Supported By China Data
Next Generation Gene Therapeutics is fast-tracking clinical trials in the US for its gene therapy candidates for Bietti's crystalline dystrophy and classic phenylketonuria, supported by China data, the Chinese venture's CEO says in an interview.
